Markets
BMY

Bristol-Myers Squibb (BMY) Gains As Market Dips: What You Should Know

In the latest trading session, Bristol-Myers Squibb (BMY) closed at $53.64, marking a +0.37% move from the previous day. This move outpaced the S&P 500's daily loss of 0.02%. At the same time, the Dow added 0.29%, and the tech-heavy Nasdaq lost 0.39%.

Coming into today, shares of the biopharmaceutical company had gained 1.62% in the past month. In that same time, the Medical sector lost 0.19%, while the S&P 500 lost 2.56%.

Investors will be hoping for strength from BMY as it approaches its next earnings release, which is expected to be January 24, 2019. On that day, BMY is projected to report earnings of $0.84 per share, which would represent year-over-year growth of 23.53%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $5.99 billion, up 9.85% from the year-ago period.

BMY's full-year Zacks Consensus Estimates are calling for earnings of $3.87 per share and revenue of $22.58 billion. These results would represent year-over-year changes of +28.57% and +8.68%, respectively.

Investors might also notice recent changes to analyst estimates for BMY. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.

Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. BMY is currently a Zacks Rank #1 (Strong Buy).

Looking at its valuation, BMY is holding a Forward P/E ratio of 13.8. Its industry sports an average Forward P/E of 14.67, so we one might conclude that BMY is trading at a discount comparatively.

Meanwhile, BMY's PEG ratio is currently 1.49. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 2.07 as of yesterday's close.

The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 61, putting it in the top 24% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report

To read this article on Zacks.com click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

BMY

Other Topics

Investing Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More